976 results about "Nasal Cavity Epithelium" patented technology

Sinusitis, enlarged nasal turbinates, tumors, infections, hearing disorders, allergic conditions, facial fractures and other disorders of the ear, nose and throat are diagnosed and/or treated using minimally invasive approaches and, in many cases, flexible catheters as opposed to instruments having rigid shafts. Various diagnostic procedures and devices are used to perform imaging studies, mucus flow studies, air/gas flow studies, anatomic dimension studies, endoscopic studies and transillumination studies. Access and occluder devices may be used to establish fluid tight seals in the anterior or posterior nasal cavities/nasopharynx and to facilitate insertion of working devices (e.g., scopes, guidewires, catheters, tissue cutting or remodeling devices, electrosurgical devices, energy emitting devices, devices for injecting diagnostic or therapeutic agents, devices for implanting devices such as stents, substance eluting devices, substance delivery implants, etc.

An improvement on the structure of electric nose suction-washer consists of a body for grip and for casing a motor mechanism. At the tip of the body are the suctioning and washing units of the motor mechanism for sucking nasal fluid or washing the nasal cavity. Therein, the body is cylindrical at a suitable place of which is a droplet shaped protrusion for easy gripping. Inside a bottom of the body encases the battery case where a spring plate exists for ease of replacing batteries and for forming power connection to the motor mechanism. The inner wall of the battery case is a plurality of vertical ridges for positioning and fastening the battery case.

The present invention relates to the delivery of high flow humidified pressurised oxygen and/or air to a patient by way of a wide bore nasal cannula (30). The cannula of the present invention comprises wide bore cannula to minimise the flow resistance and the entry velocity. The nasal cannula includes two nasal prongs (40, 41) fittable into a patient's nostrils. The prongs follow the inner shape of the patient's nostrils such that a more efficient flow of gases into the patient's lungs is achieved as gases flow are directed down the main nasal passage more accurately. The cannula do not seal within the nasal cavities of the patient, and in some embodiments the cannula may be provided with a pressure relief valve to allow gases to be exhausted from the cannula.

Described herein are nasal respiratory devices and methods for treating a variety of medical diseases including snoring and sleep apnea through the use of such devices. In general, these devices include an airflow resistor, such as a flap valve and a holdfast for securing the device in communication with the subject's nasal cavity. The devices may be configured to include leak paths to regulate the expiratory pressure when worn by a subject. Methods for using these devices may include securing a device over or at least partially within (or both of) a subject's nasal cavities.

A method for cerebral and systemic cooling by providing a nebulized liquid having a boiling point of 38-300° C. The nebulized liquid is delivered as a mist or a spray via the nasal and/or oral cavities of a patient. The mist causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis. Compositions and medical devices for cerebral and systemic cooling are also provided. Cooling assemblies, and methods of use, are also provided that include flexible balloon assemblies that are inserted to various locations in a patient's body. The flexible balloons are then infused with a liquid having a temperature between about −20° C. and about 37° C. The flexible balloon assemblies can be inserted into the nasal cavity, oral cavity, throat, stomach, and other locations to effect cerebral cooling.

This invention is for nasal adaptors for oral inhaler devices and methods of adapting an oral inhaler device with a nasal adaptor. The nasal adaptor of the present invention, in assembly with an oral metered dose aerosol inhaler converts an oral inhaler device to nasal delivery. The nasal adaptor in assembly with an oral inhaler device when in operation, simultaneously administers an inhalant to the nasal mucosa and down to the bronchial tree and lungs. In this manner a nasally delivered anti-inflammatory agent would travel down the same route as an allergen would—the nostril, nasal cavity, nasopharynx, trachea, bronchi and lung tissues.

The present invention is directed to a mucoadhesive delivery system for the local or systemic administration of a pharmaceutical agent. The delivery system of the invention effectively and facilely enables transport of the pharmaceutical agent through mucosal membranes and into the vasculattire of the mucosa. The delivery system includes an at least partially water soluble bioadhesive layer and an at least partially water soluble backing layer. Incorporated within either or both of these layers are the pharmaceutical agent and a mucosal penetration enhancing agent. The mucosal penetration enhancing agent displays localized tissue irritation properties. The mucoadhesive delivery system may be in the form of a gel, film, disc or patch. It may be applied to any mucosal membrane of a patient including but not limited to those of the buccal and nasal cavities, throat, eye, vagina, alimentary tract and peritoneum.

A foldable brush self-sampling device for collecting of cell specimens from a body cavity, such as cervix, endometrium, rectum, nasal cavity and fauces, for diagnostic purposes, allows a user to collect cell specimens in the privacy of home. The device includes a sheath and a brush bar. The brush bar would fold into the sheath, which is with smaller diameter. The user inserts the sheath into the cavity easily and pushes the brush bar to expose the brush elements. After insertion of the sheath and push of the brush bar, the brush bar is rotated to obtain the specimen from the body cavity and then retracted in order to return the sheath.

The present invention is embodied in a portable self contained ventilating appliance, including an interface device coupled to at least one of an oral cavity or nasal cavity of a user, a ventilation device physically extending from the interface and configured to deliver pressurized air to the user through the interface, and a sensor monitoring system coupled to the interface and the ventilation device and configured to monitor the user.

A respiration nozzle has a hollow body with a front and a rear, at least one outlet made of a resilient membrane, and two inflatable nasal tubes. The at least one outlet is formed on the front of the hollow body and has a cross-shaped slit valve defined in the membrane to temporarily open and release air from the respiration nozzle. The two inflatable nasal tubes are formed on the rear of the hollow body and are enabled to inflate when air is pumped into the respiration nozzle. Therefore, air pressure inside the respiration nozzle is kept at a positive pressure to minimize consumption of electricity when pumping the air. Meanwhile, the inflatable nasal tubes gently and evenly match the nasal cavities without causing any uncomfortable feeling to the wearer.

Chronic sinusitis is treated by the application of cold plasma or plasma-activated species to the infected mucosal surfaces through use of an endoscope having a steerable end which may be projected into the sinus cavities through the nasal cavity. The cold plasma is generated at either the distal end of the endoscope with a power source by application of a power, or at the distal end by gas and electrical connections extending through the endoscope. The cold plasma or plasma-activated species act to destroy bacterial cells but not eukaryotic cells.

A method for treating nasal cavity irritation, such as symptoms of allergic rhinitis. The method includes inserting a plug of a frozen liquid into a nasal cavity of a patient experiencing nasal irritation. The method also includes holding the plug against a lining of the nasal cavity to reduce the irritation.

A method for treating amyotrophic lateral sclerosis (ALS) in a human subject is provided. A first vibration stimulation member is introduced into a posterior part of a first nasal cavity of the human subject. By means of the first vibration stimulation member, vibrations are imparted to the posterior part of the first nasal cavity at frequency in a range of from 60 to 70 Hz. A second vibration simulation member is arranged between the trapezius muscle and the sternocleidomastoid muscle on a first side of the neck of the human subject; and by means of said second vibration stimulation member, vibrations are imparted to the first side of the neck at a frequency in a range of from 30 to 50 Hz.

Particular aspects provide novel atomizers for generating particles over a broad range of MMAD size distributions, the eliminating the requirement for an impaction baffle in generating the desired particle sizes. In particular aspects, the atomization means communicates with a remote particle filter member configured and positioned to provide for particle size filtering. In additional aspects, the atomization means communicates with a particle dispersion chamber suitable to impart a desired particle flow pattern to particles within and exiting the dispersion chamber. In further aspects, the atomization means communicates with a nasal, ocular, oral or ‘vicinity’ adapter. The novel devices provide for targeted (e.g., nasal, ocular, oral, local vicinity), systemic, and/or topical delivery of an atomized liquid (e.g., via the nasal cavity, olfactory region, and mouth). Further exemplary aspects relate to aerosolization and delivery of perfume, fragrance, essential oil or cosmeceutical agents and the like.

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.

The present invention relates to powdery inhalant compositions, each of which contains a steroidal anti-inflammatory drug, a carrier and water and has a water activity at 25° C. of from 0.35 to 0.75. Each powdery inhalant composition according to the present invention is high in the delivery rate of its steroidal anti-inflammatory drug to an inhalation target site from the nasal cavities or oral cavity, that is, to the alveoli, the bronchioles, the bronchial tubes or the airway, and allows the steroidal anti-inflammatory to exhibit its superb therapeutic effects.

A system and method of training the proper placement of an endotracheal tube in a training manikin's trachea using a live video camera located inside the manikin for simultaneous remote display of the manikin's trachea and surrounding area and the relative positioning of the laryngoscope blade and endotracheal tube. The system includes a training manikin, a micro video camera mounted adjacent the nasal cavity of the manikin, with the camera directed at the trachea, a monitor displaying the images being captured by the video camera, and electrical connection connecting the video camera to said monitor.

A medical device and method for treating nose bleeds are provided. The device includes packing material interconnected to a flange member. The packing material is insertable into a nasal cavity, for absorbing blood and other body fluids. The flange member prevents the packing material from being inhaled or otherwise moving in an anterior direction. In addition, the flange member obscures a view of the interior of the user's nasal cavity, and therefore of blood within the cavity, or of blood that has been absorbed by the packing member.